Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC34H30FN9O2S |
InChIKeyGNAZHLWOOVUAFO-MHZLTWQESA-N |
CAS Registry2851986-83-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | AT | 21 Feb 2024 |